Teriparatide Replacement Therapy for Hypoparathyroidism During Treatment With Lenvatinib for Advanced Thyroid Cancer: A Case Report

Teriparatide Replacement Therapy for Hypoparathyroidism During Treatment With Lenvatinib for Advanced Thyroid Cancer: A Case Report

Thyroid cancer metastasizes in 4% of cases. Approximately two-thirds of these patients are refractory to radioactive iodine-131 (RAI) therapy and have a poor 10-year survival prognosis. Treatment with tyrosine kinase inhibitors (TKIs) may be administered in selected RAI-refractory patients. However,...

Full description

Bibliographic Details
Main Authors: Tommaso Porcelli, Francesca Sessa, Angela Caputo, Christian Catalini, Domenico Salvatore
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-05-01
Series:Frontiers in Endocrinology
Subjects:
metastatic thyroid cancer
tyrosine kinase inhibitors
targeted therapy
lenvatinib
postsurgical hypoparathyroidism
recombinant human parathyroid hormone (1–34)
Online Access:http://journal.frontiersin.org/article/10.3389/fendo.2018.00244/full

Internet

http://journal.frontiersin.org/article/10.3389/fendo.2018.00244/full

Similar Items